Nested case-control study of the association of circulating levels of serum insulin-like growth factor I and insulin-like growth factor binding protein 3 with breast cancer in young women in Norway

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 8, 2008, Pages 2097-2100

  Vatten, Lars J ^a,b,e   Holly, Jeff M ^c   Gunnell, David ^c   Tretli, Steinar ^a,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e University Medical Center   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LOGISTIC MODELS; NORWAY; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 54049158976     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0212     Document Type: Article

References (22)

1. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor and risk of breast cancer. Lancet 1998;351:1393-96.
2. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
3. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006;13:273-8.
4. Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:2-19.
5. Ng ST, Zhou J, Adesanya OO, Wang J, leRoith D, Bondy CA. Growth hormone treatment induces mamary gland hyperplasia in aging primates. Nat Med 1997;3:1141-4.
6. Stewart CE, Rotwein P. Growth, differentiation and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996;76:1005-26.
7. Baserga R. The insulin-like growth factor receptor: a key to tumor growth? Cancer Res 1995;55:249-52.
8. Holly J. Insulin-like growth factor I and new opportunities for cancer prevention. Lancet 1998;351:1373.
9. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
10. Ma J, Pollak MN, Giovannucci E. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
11. Yu H, Spitz MR, Mistry J, Gu J, WK Hong, X Wu. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
12. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344-50.
13. Stensvold I, Tverdal A, Foss OP. The effect of coffee on blood lipids and blood pressure. Results from a Norwegian cross-sectional study, men and women, 40-42 years. J Clin Epidemiol 1989;42:877-84.
14. Bjartveit K, Stensvold I, Lund-Larsen PG, Gjervig T, Kruger O, Urdal P. Cardiovascular screenings in Norwegian counties. Background and implementation. Status of risk pattern during the period 1985-90 among persons 40-42 years in 14 counties. Tidsskr Nor Laegeforen (English abstract) 1991;111:2063-72.
15. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus Serum Bank in Norway. Cancer Epidemiol Biomarkers Prev 1997;6:967-9.
16. Cheetham TD, Holly JM, Baxter RC, et al. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1998;157:81-7.
17. Rinaldi S, Peeters PHM, Berrino F, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2006;13:593-605.
18. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699-704.
19. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, their binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in the Nurses Health Study II. Endocr Relat Cancer 2006;13:583-92.
20. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998;9:570-3.
21. Skjeldestad FE. Choice of contraceptive modality by women in Norway. Acta Obstet Gynecol Scand 1993;72:48-52.
22. Trichopoulos D, Bamia C, Lagiou P, Trichopoulo A. Are mammotropic hormones mainly permissive for the development of breast cancer? Int J Cancer 2006;118:2863-5.